Regulatory Focus™ > News Articles > Perspective: Evaluating Regulator Risk for Comparator Drug Products

Perspective: Evaluating Regulator Risk for Comparator Drug Products

Posted 01 May 2011 | By Cesar Medina, MBA, RAC Ferno Alvarez-Nunex, PhD 

Evaluating risks and developing mitigation strategies have become common industry practices in drug development. Regulatory agencies have adopted risk-based approaches in quality management, pharmaceutical development and postmarket surveillance of medicinal products.1-4

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe